Welcome to our dedicated page for NANOVIRICIDES SEC filings (Ticker: NNVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NANOVIRICIDES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NANOVIRICIDES's regulatory disclosures and financial reporting.
NanoViricides, Inc. entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC, permitting the company to issue and sell shares of its common stock from time to time in an “at the market” offering under its existing Form S-3 shelf registration statement. Sales, if any, may occur on the NYSE American or other trading markets, or in privately negotiated transactions with the company’s prior written consent, based on parameters set in placement notices.
The company will pay the sales agent a 2.0% commission on the aggregate gross proceeds from any stock sales. The Placement Shares will be issued under the registration statement and a prospectus supplement filed on July 17, 2026, and the program will terminate when all such shares are sold or the agreement is ended by either party. A legal opinion from Lucosky Brookman LLP on the validity of the Placement Shares is included as an exhibit.
NanoViricides, Inc. is undertaking an at‑the‑market offering of up to $4,018,069 of common stock under a Sales Agreement with D. Boral Capital LLC, which will act as sales agent or principal and receive a 2% commission on gross sales.
The company may sell shares from time to time on NYSE American or other permitted markets, with no minimum sale amount and no escrow. An illustrative case assumes issuance of 2,660,973 shares at $1.51 per share, increasing shares outstanding from 22,982,816 to up to 25,643,789, causing immediate dilution of about $0.99 per share versus the assumed offering price.
As of July 10, 2026, public float was about $41,583,701 (22,356,829 non‑affiliate shares at $1.86). The company has sold approximately $9,843,165 of common stock under Form S‑3 General Instruction I.B.6 in the prior 12 months and is subject to the one‑third‑of‑float cap for primary offerings while float remains below $75 million. Net proceeds will be used for general corporate purposes, including working capital, R&D and clinical trial spending.
NanoViricides, Inc. registers for resale up to 1,333,334 shares of Common Stock issuable upon exercise of Common Stock Purchase Warrants issued in a registered direct offering. The Company will not receive proceeds from resales by the Selling Stockholder; if the Common Warrants are exercised for cash, the Company would receive approximately $2.33 million.
The prospectus lists 22,982,816 shares outstanding as of June 4, 2026 and describes the Offering structure (1,133,334 common shares, 200,000 pre-funded warrants and 1,333,334 Common Warrants issued May 15, 2026). The Selling Stockholder named is Orca Capital AG, which may offer shares at varied prices and by multiple methods; discounts and selling commissions will be borne by the Selling Stockholder.
NanoViricides, Inc. files a Form S-3 to register for resale up to 1,333,334 shares of Common Stock issuable upon exercise of Common Stock Purchase Warrants issued in a registered direct offering.
The prospectus states the Company will not receive proceeds from resales by the selling stockholder but would receive approximately $2.33 million in gross proceeds if the Common Warrants are exercised in full at an exercise price of $1.75 per share. Shares outstanding were 22,982,816 as of June 15, 2026, and the post-offering share count assumes full exercise would be 24,316,150.
NanoViricides, Inc. filed a shelf registration on Form S-3 to offer up to $50,000,000 of various securities, including common stock, preferred stock, debt, warrants, rights and units, with specific terms to be set in prospectus supplements.
The prospectus states 22,982,816 shares of Common Stock outstanding as of June 4, 2026, 918,422 shares of Series A Preferred outstanding, and an aggregate market value of Common Stock held by non-affiliates of approximately $35,500,000 based on a $1.59 closing price on June 2, 2026.
NanoViricides, Inc. reported that its President and Executive Chairman, Dr. Anil R. Diwan, participated in the Alliance Global Partners Healthcare Companies Showcase on May 20, 2026, in a fireside chat with A.G.P. equity research analyst Dr. James Molloy.
During the discussion, Dr. Diwan described two antiviral drug candidates developed during COVID-19: NV-387, a broad-spectrum antiviral now entering a Phase II clinical trial against Mpox in the Democratic Republic of Congo, and a backup candidate where remdesivir is encapsulated within NV-387 nanoviricide micelles as an oral formulation.
He explained that remdesivir has prior Ebola clinical trial and safety data, that NV-387 encapsulation is designed to protect remdesivir from rapid metabolism based on animal studies and a peer‑reviewed PLOS One publication, and that the company maintains both NV-387 alone and NV-387 with remdesivir as candidates the company expects could address the current Ebola Bundibugyo strain in DRC, subject to public health authorities’ decisions.
NanoViricides, Inc. entered into a registered direct offering with a single institutional investor, raising approximately $2.0 million in gross proceeds through common shares or pre-funded warrants plus accompanying common warrants. The securities were priced at $1.50 per share (or $1.49999 per pre-funded warrant), with warrants to purchase 1,333,334 shares at an exercise price of $1.75 per share.
The financing closed after effectiveness of the company’s Form S-3 shelf registration and includes a 30-day restriction on most new equity issuances, a 10-day pause on at-the-market sales, and a 30-day CEO lock-up. NanoViricides plans to use net proceeds for working capital, capital expenditures, research and development, clinical trials, and potential acquisitions or other strategic purposes.
NanoViricides, Inc. is conducting a registered direct offering of 1,333,334 shares of Common Stock, pre-funded warrants to purchase up to 200,000 shares and common warrants to purchase up to 1,333,334 shares at stated prices. The shares are offered at $1.50 per share, pre-funded warrants at $1.49999 each and common warrants exercisable at $1.75. Net proceeds to the company are expected to be approximately $1.735M, and delivery is expected on or about May 18, 2026. The prospectus supplement notes 22,780,334 shares outstanding immediately after the Offering and discloses a going-concern qualification tied to cash needs and anticipated future financings.